{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T01:38:19Z","timestamp":1790645899234,"version":"4.1.0"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"35","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2015,8,27]]},"DOI":"10.1038\/onc.2014.383","type":"journal-article","created":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T11:12:02Z","timestamp":1417432322000},"page":"4581-4590","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The activation loop tyrosine 823 is essential for the transforming capacity of the c-Kit oncogenic mutant D816V"],"prefix":"10.1038","volume":"34","author":[{"given":"S","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J U","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mohlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"P\u00e5hlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"R\u00f6nnstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,1]]},"reference":[{"key":"BFonc2014383_CR1","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/S1357-2725(99)00076-X","volume":"31","author":"LK Ashman","year":"1999","unstructured":"Ashman LK . The biology of stem cell factor and its receptor C-kit. Int J Biochem Cell Biol 1999; 31: 1037\u20131051.","journal-title":"Int J Biochem Cell Biol"},{"key":"BFonc2014383_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/hupa.2002.124124","volume":"33","author":"MC Heinrich","year":"2002","unstructured":"Heinrich MC, Rubin BP, Longley BJ, Fletcher JA . Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol 2002; 33: 484\u2013495.","journal-title":"Hum Pathol"},{"key":"BFonc2014383_CR3","doi-asserted-by":"publisher","first-page":"e1002661","DOI":"10.1371\/journal.pcbi.1002661","volume":"8","author":"E Laine","year":"2012","unstructured":"Laine E, Auclair C, Tchertanov L . Allosteric communication across the native and mutated KIT receptor tyrosine kinase. PLoS Comput Biol 2012; 8: e1002661.","journal-title":"PLoS Comput Biol"},{"key":"BFonc2014383_CR4","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0002-9440(10)63120-3","volume":"164","author":"K Kemmer","year":"2004","unstructured":"Kemmer K, Corless CL, Fletcher JA, McGreevey L, Haley A, Griffith D et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004; 164: 305\u2013313.","journal-title":"Am J Pathol"},{"key":"BFonc2014383_CR5","first-page":"920","volume":"89","author":"A Beghini","year":"2004","unstructured":"Beghini A, Ripamonti CB, Cairoli R, Cazzaniga G, Colapietro P, Elice F et al. KIT activating mutations: incidence in adult and pediatric acute myeloid leukemia, and identification of an internal tandem duplication. Haematologica 2004; 89: 920\u2013925.","journal-title":"Haematologica"},{"key":"BFonc2014383_CR6","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1182\/blood-2005-09-3640","volume":"107","author":"R Cairoli","year":"2006","unstructured":"Cairoli R, Beghini A, Grillo G, Nadali G, Elice F, Ripamonti CB et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463\u20133468.","journal-title":"Blood"},{"key":"BFonc2014383_CR7","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S0002-9440(10)65419-3","volume":"154","author":"Q Tian","year":"1999","unstructured":"Tian Q, Frierson HF Jr, Krystal GW, Moskaluk CA . Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999; 154: 1643\u20131647.","journal-title":"Am J Pathol"},{"key":"BFonc2014383_CR8","first-page":"7674","volume":"63","author":"LH Looijenga","year":"2003","unstructured":"Looijenga LH, de Leeuw H, van Oorschot M, van Gurp RJ, Stoop H, Gillis AJ et al. Stem cell factor receptor (c-KIT) codon 816 mutations predict development of bilateral testicular germ-cell tumors. Cancer Res 2003; 63: 7674\u20137678.","journal-title":"Cancer Res"},{"key":"BFonc2014383_CR9","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","volume":"96","author":"BJ Longley Jr","year":"1999","unstructured":"Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci USA 1999; 96: 1609\u20131614.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFonc2014383_CR10","doi-asserted-by":"crossref","first-page":"3117","DOI":"10.1182\/blood.V87.8.3117.bloodjournal8783117","volume":"87","author":"X Piao","year":"1996","unstructured":"Piao X, Bernstein A . A point mutation in the catalytic domain of c-kit induces growth factor independence, tumorigenicity, and differentiation of mast cells. Blood 1996; 87: 3117\u20133123.","journal-title":"Blood"},{"key":"BFonc2014383_CR11","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1182\/blood.V98.5.1365","volume":"98","author":"R Chian","year":"2001","unstructured":"Chian R, Young S, Danilkovitch-Miagkova A, R\u00f6nnstrand L, Leonard E, Ferrao P et al. Phosphatidylinositol 3 kinase contributes to the transformation of hematopoietic cells by the D816V c-Kit mutant. Blood 2001; 98: 1365\u20131373.","journal-title":"Blood"},{"key":"BFonc2014383_CR12","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3109\/10428190109060342","volume":"41","author":"ZQ Ning","year":"2001","unstructured":"Ning ZQ, Li J, Arceci RJ . Activating mutations of c-kit at codon 816 confer drug resistance in human leukemia cells. Leuk Lymphoma 2001; 41: 513\u2013522.","journal-title":"Leuk Lymphoma"},{"key":"BFonc2014383_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","volume":"66","author":"MM Schittenhelm","year":"2006","unstructured":"Schittenhelm MM, Shiraga S, Schroeder A, Corbin AS, Griffith D, Lee FY et al. Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res 2006; 66: 473\u2013481.","journal-title":"Cancer Res"},{"key":"BFonc2014383_CR14","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","volume":"108","author":"NP Shah","year":"2006","unstructured":"Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C . Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006; 108: 286\u2013291.","journal-title":"Blood"},{"key":"BFonc2014383_CR15","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1038\/sj.onc.1210159","volume":"26","author":"O Kosmider","year":"2007","unstructured":"Kosmider O, Denis N, Dubreuil P, Moreau-Gachelin F . Semaxinib (SU5416) as a therapeutic agent targeting oncogenic Kit mutants resistant to imatinib mesylate. Oncogene 2007; 26: 3904\u20133908.","journal-title":"Oncogene"},{"key":"BFonc2014383_CR16","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","volume":"107","author":"KV Gleixner","year":"2006","unstructured":"Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, B\u00f6hm A et al. PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects. Blood 2006; 107: 752\u2013759.","journal-title":"Blood"},{"key":"BFonc2014383_CR17","doi-asserted-by":"publisher","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","volume":"114","author":"KJ Aichberger","year":"2009","unstructured":"Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V et al. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 2009; 114: 5342\u20135351.","journal-title":"Blood"},{"key":"BFonc2014383_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","volume":"138","author":"A Orfao","year":"2007","unstructured":"Orfao A, Garcia-Montero AC, Sanchez L, Escribano L, REMA. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007; 138: 12\u201330.","journal-title":"Br J Haematol"},{"key":"BFonc2014383_CR19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jmgm.2004.04.003","volume":"23","author":"R Foster","year":"2004","unstructured":"Foster R, Griffith R, Ferrao P, Ashman L . Molecular basis of the constitutive activity and STI571 resistance of Asp816Val mutant KIT receptor tyrosine kinase. J Mol Graph Model 2004; 23: 139\u2013152.","journal-title":"J Mol Graph Model"},{"key":"BFonc2014383_CR20","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1093\/jb\/mvq015","volume":"147","author":"JP DiNitto","year":"2010","unstructured":"DiNitto JP, Deshmukh GD, Zhang Y, Jacques SL, Coli R, Worrall JW et al. Function of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistance. J Biochem 2010; 147: 601\u2013609.","journal-title":"J Biochem"},{"key":"BFonc2014383_CR21","doi-asserted-by":"publisher","first-page":"22460","DOI":"10.1074\/jbc.M113.474072","volume":"288","author":"S Agarwal","year":"2013","unstructured":"Agarwal S, Kazi JU, R\u00f6nnstrand L . Phosphorylation of the activation loop tyrosine 823 in c-Kit is crucial for cell survival and proliferation. J Biol Chem 2013; 288: 22460\u201322468.","journal-title":"J Biol Chem"},{"key":"BFonc2014383_CR22","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V85.3.790.bloodjournal853790","volume":"85","author":"H Kitayama","year":"1995","unstructured":"Kitayama H, Kanakura Y, Furitsu T, Tsujimura T, Oritani K, Ikeda H et al. Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumorigenicity of factor-dependent hematopoietic cell lines. Blood 1995; 85: 790\u2013798.","journal-title":"Blood"},{"key":"BFonc2014383_CR23","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clml.2012.08.004","volume":"13","author":"H Bougherara","year":"2013","unstructured":"Bougherara H, Georgin-Lavialle S, Damaj G, Launay JM, Lhermitte L, Auclair C et al. Relocalization of KIT D816V to cell surface after dasatinib treatment: potential clinical implications. Clin Lymphoma Myeloma Leuk 2013; 13: 62\u201369.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"BFonc2014383_CR24","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1016\/j.cellsig.2009.06.002","volume":"21","author":"K Masson","year":"2009","unstructured":"Masson K, R\u00f6nnstrand L . Oncogenic signaling from the hematopoietic growth factor receptors c-Kit and Flt3. Cell Signal 2009; 21: 1717\u20131726.","journal-title":"Cell Signal"},{"key":"BFonc2014383_CR25","doi-asserted-by":"publisher","first-page":"11039","DOI":"10.1074\/jbc.M808058200","volume":"284","author":"J Sun","year":"2009","unstructured":"Sun J, Pedersen M, R\u00f6nnstrand L . The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction. J Biol Chem 2009; 284: 11039\u201311047.","journal-title":"J Biol Chem"},{"key":"BFonc2014383_CR26","doi-asserted-by":"publisher","first-page":"20059","DOI":"10.1074\/jbc.R700016200","volume":"282","author":"C Schindler","year":"2007","unstructured":"Schindler C, Levy DE, Decker T . JAK-STAT signaling: from interferons to cytokines. J Biol Chem 2007; 282: 20059\u201320063.","journal-title":"J Biol Chem"},{"key":"BFonc2014383_CR27","doi-asserted-by":"publisher","first-page":"5956","DOI":"10.1074\/jbc.M110.182642","volume":"286","author":"A Chaix","year":"2011","unstructured":"Chaix A, Lopez S, Voisset E, Gros L, Dubreuil P, De Sepulveda P . Mechanisms of STAT protein activation by oncogenic KIT mutants in neoplastic mast cells. J Biol Chem 2011; 286: 5956\u20135966.","journal-title":"J Biol Chem"},{"key":"BFonc2014383_CR28","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/0959-437X(94)90086-8","volume":"4","author":"GA Rodrigues","year":"1994","unstructured":"Rodrigues GA, Park M . Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 1994; 4: 15\u201324.","journal-title":"Curr Opin Genet Dev"},{"key":"BFonc2014383_CR29","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1172\/JCI116761","volume":"92","author":"T Furitsu","year":"1993","unstructured":"Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993; 92: 1736\u20131744.","journal-title":"J Clin Invest"},{"key":"BFonc2014383_CR30","doi-asserted-by":"crossref","unstructured":"Chaix A, Arcangeli ML, Lopez S, Voisset E, Yang Y, Vita M et al. KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570. Oncogene 2013.","DOI":"10.1038\/onc.2013.12"},{"key":"BFonc2014383_CR31","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/j.1460-2075.1995.tb07023.x","volume":"14","author":"H Serve","year":"1995","unstructured":"Serve H, Yee NS, Stella G, Sepp-Lorenzino L, Tan JC, Besmer P . Differential roles of PI3-kinase and Kit tyrosine 821 in Kit receptor-mediated proliferation, survival and cell adhesion in mast cells. EMBO J 1995; 14: 473\u2013483.","journal-title":"EMBO J"},{"key":"BFonc2014383_CR32","doi-asserted-by":"publisher","first-page":"7059","DOI":"10.1128\/MCB.24.16.7059-7071.2004","volume":"24","author":"JL Boerner","year":"2004","unstructured":"Boerner JL, Demory ML, Silva C, Parsons SJ . Phosphorylation of Y845 on the epidermal growth factor receptor mediates binding to the mitochondrial protein cytochrome c oxidase subunit II. Mol Cell Biol 2004; 24: 7059\u20137071.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014383_CR33","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1002\/mc.20138","volume":"44","author":"JL Boerner","year":"2005","unstructured":"Boerner JL, Biscardi JS, Silva CM, Parsons SJ . Transactivating agonists of the EGF receptor require Tyr 845 phosphorylation for induction of DNA synthesis. Mol Carcinog 2005; 44: 262\u2013273.","journal-title":"Mol Carcinog"},{"key":"BFonc2014383_CR34","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.cellsig.2010.05.004","volume":"22","author":"P Wardega","year":"2010","unstructured":"Wardega P, Heldin CH, Lennartsson J . Mutation of tyrosine residue 857 in the PDGF beta-receptor affects cell proliferation but not migration. Cell Signal 2010; 22: 1363\u20131368.","journal-title":"Cell Signal"},{"key":"BFonc2014383_CR35","doi-asserted-by":"publisher","first-page":"19813","DOI":"10.1074\/jbc.M110.121988","volume":"285","author":"SA Hegazy","year":"2010","unstructured":"Hegazy SA, Wang P, Anand M, Ingham RJ, Gelebart P, Lai R . The tyrosine 343 residue of nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) is important for its interaction with SHP1, a cytoplasmic tyrosine phosphatase with tumor suppressor functions. J Biol Chem 2010; 285: 19813\u201319820.","journal-title":"J Biol Chem"},{"key":"BFonc2014383_CR36","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1210\/mend.11.12.0014","volume":"11","author":"LQ Dong","year":"1997","unstructured":"Dong LQ, Farris S, Christal J, Liu F . Site-directed mutagenesis and yeast two-hybrid studies of the insulin and insulin-like growth factor-1 receptors: the Src homology-2 domain-containing protein hGrb10 binds to the autophosphorylated tyrosine residues in the kinase domain of the insulin receptor. Mol Endocrinol 1997; 11: 1757\u20131765.","journal-title":"Mol Endocrinol"},{"key":"BFonc2014383_CR37","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R . STATs in oncogenesis. Oncogene 2000; 19: 2474\u20132488.","journal-title":"Oncogene"},{"key":"BFonc2014383_CR38","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1182\/blood-2002-04-1204","volume":"101","author":"M Benekli","year":"2003","unstructured":"Benekli M, Baer MR, Baumann H, Wetzler M . Signal transducer and activator of transcription proteins in leukemias. Blood 2003; 101: 2940\u20132954.","journal-title":"Blood"},{"key":"BFonc2014383_CR39","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1128\/MCB.18.5.2553","volume":"18","author":"JF Bromberg","year":"1998","unstructured":"Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell JE Jr . Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998; 18: 2553\u20132558.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014383_CR40","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1084\/jem.183.3.811","volume":"183","author":"N Carlesso","year":"1996","unstructured":"Carlesso N, Frank DA, Griffin JD . Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr\/Abl. J Exp Med 1996; 183: 811\u2013820.","journal-title":"J Exp Med"},{"key":"BFonc2014383_CR41","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1128\/MCB.20.5.1699-1712.2000","volume":"20","author":"L Goutebroze","year":"2000","unstructured":"Goutebroze L, Brault E, Muchardt C, Camonis J, Thomas G . Cloning and characterization of SCHIP-1, a novel protein interacting specifically with spliced isoforms and naturally occurring mutant NF2 proteins. Mol Cell Biol 2000; 20: 1699\u20131712.","journal-title":"Mol Cell Biol"},{"key":"BFonc2014383_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1007\/s12094-012-0928-6","volume":"15","author":"N Wu","year":"2013","unstructured":"Wu N, Liu S, Guo C, Hou Z, Sun MZ . The role of annexin A3 playing in cancers. Clin Transl Oncol 2013; 15: 106\u2013110.","journal-title":"Clin Transl Oncol"},{"key":"BFonc2014383_CR43","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1007\/s10585-011-9420-x","volume":"28","author":"PV Giridhar","year":"2011","unstructured":"Giridhar PV, Funk HM, Gallo CA, Porollo A, Mercer CA, Plas DR et al. Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells. Clin Exp Metastasis 2011; 28: 887\u2013897.","journal-title":"Clin Exp Metastasis"},{"key":"BFonc2014383_CR44","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1161\/CIRCRESAHA.109.208785","volume":"105","author":"W Zhu","year":"2009","unstructured":"Zhu W, Trivedi CM, Zhou D, Yuan L, Lu MM, Epstein JA . Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness. Circ Res 2009; 105: 1240\u20131247.","journal-title":"Circ Res"},{"key":"BFonc2014383_CR45","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1756-8722-6-12","volume":"6","author":"N An","year":"2013","unstructured":"An N, Kraft AS, Kang Y . Abnormal hematopoietic phenotypes in Pim kinase triple knockout mice. J Hematol Oncol 2013; 6: 12.","journal-title":"J Hematol Oncol"},{"key":"BFonc2014383_CR46","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.bcp.2012.09.018","volume":"85","author":"C Blanco-Aparicio","year":"2013","unstructured":"Blanco-Aparicio C, Carnero A . Pim kinases in cancer: diagnostic, prognostic and treatment opportunities. Biochem Pharmacol 2013; 85: 629\u2013643.","journal-title":"Biochem Pharmacol"},{"key":"BFonc2014383_CR47","doi-asserted-by":"publisher","first-page":"3491","DOI":"10.1182\/blood-2012-02-412643","volume":"120","author":"Q Yang","year":"2012","unstructured":"Yang Q, Chen LS, Neelapu SS, Miranda RN, Medeiros LJ, Gandhi V . Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma. Blood 2012; 120: 3491\u20133500.","journal-title":"Blood"},{"key":"BFonc2014383_CR48","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1084\/jem.20082074","volume":"206","author":"R Grundler","year":"2009","unstructured":"Grundler R, Brault L, Gasser C, Bullock AN, Dechow T, Woetzel S et al. Dissection of PIM serine\/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration. J Exp Med 2009; 206: 1957\u20131970.","journal-title":"J Exp Med"},{"key":"BFonc2014383_CR49","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.yexcr.2012.12.021","volume":"319","author":"M Shahidul Makki","year":"2013","unstructured":"Shahidul Makki M, Cristy Ruteshouser E, Huff V . Ubiquitin specific protease 18 (Usp18) is a WT1 transcriptional target. Exp Cell Res 2013; 319: 612\u2013622.","journal-title":"Exp Cell Res"},{"key":"BFonc2014383_CR50","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3892\/or.2013.2459","volume":"30","author":"WY Zhuang","year":"2013","unstructured":"Zhuang WY, Cen JN, Zhao Y, Chen ZX . Epigenetic silencing of Bcl-2, CEBPA and p14ARF by the AML1-ETO oncoprotein contributing to growth arrest and differentiation block in the U937 cell line. Oncol Rep 2013; 30: 185\u2013192.","journal-title":"Oncol Rep"},{"key":"BFonc2014383_CR51","doi-asserted-by":"publisher","first-page":"2165","DOI":"10.1182\/blood-2013-01-480392","volume":"121","author":"C Thieblemont","year":"2013","unstructured":"Thieblemont C, Briere J . MYC, BCL2, BCL6 in DLBCL: impact for clinics in the future? Blood 2013; 121: 2165\u20132166.","journal-title":"Blood"},{"key":"BFonc2014383_CR52","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1002\/j.1460-2075.1993.tb06104.x","volume":"12","author":"P Blume-Jensen","year":"1993","unstructured":"Blume-Jensen P, Siegbahn A, Stabel S, Heldin CH, R\u00f6nnstrand L . Increased Kit\/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. EMBO J 1993; 12: 4199\u20134209.","journal-title":"EMBO J"},{"key":"BFonc2014383_CR53","doi-asserted-by":"publisher","first-page":"27444","DOI":"10.1074\/jbc.M709703200","volume":"283","author":"J Sun","year":"2008","unstructured":"Sun J, Pedersen M, R\u00f6nnstrand L . Gab2 is involved in differential phosphoinositide 3-kinase signaling by two splice forms of c-Kit. J Biol Chem 2008; 283: 27444\u201327451.","journal-title":"J Biol Chem"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/onc2014383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014383","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/onc2014383.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T20:30:49Z","timestamp":1647894649000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/onc2014383"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,1]]},"references-count":53,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2015,8,27]]}},"alternative-id":["BFonc2014383"],"URL":"https:\/\/doi.org\/10.1038\/onc.2014.383","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,1]]},"assertion":[{"value":"30 June 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2014","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2014","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2014","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}